Impact Factor 6.244 | CiteScore 3.9
More on impact ›
This section focuses on the investigation of tumorigenesis, prevention, early detection and treatment of hepato pancreatic biliary neoplasia, with a particular interest in multidisciplinary research to support clinical applications of biological advances.
There are special considerations for submission to this section and authors are kindly encouraged to consult them in full by clicking "Read More" below.
The Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers section aims at offering a wide and comprehensive approach to investigations concerning tumorigenesis, prevention, early detection and treatment of HPB neoplasia. Even though the molecular machinery triggering and sustaining HPB carcinogenesis and the morphogenetic pathways leading to cancer is, at least in part, well-established, knowledge has only been incompletely translated to the single patient care and population-based interventions, in spite of the technological novelties in endoscopy and imaging of HPB tumors and their tailored treatments.
The ultimate effort of the section is, therefore, to support multidisciplinary research in order to speed up clinical applications of biological advances. For these reasons this section specifically welcomes contributions on the following topics:
While we welcome meta-analyses and descriptive studies (including those submitted as Original Research), these should be based on rigorous statistical methods or systematic reviews, and must bring new insights into the mechanisms of carcinogenesis. Furthermore, manuscripts focusing on cancer risk factors and stratification are not in scope for this section and should be submitted to Cancer Epidemiology and Prevention of Frontiers in Oncology.
In silico studies must be validated with a cell line study.
Submissions that are surgical in nature are not in scope for this section and should be submitted to the Surgical Oncology Section of Frontiers in Oncology.
Case Reports should include correlative data and expand the current knowledge on the pathophysiological and clinical manifestations of cancer while discussing the cellular and molecular levels of the disease.
Indexed in: Chemical Abstracts Service (CAS), CLOCKSS, CrossRef, DOAJ, Google Scholar, PubMed, PubMed Central (PMC), Scopus, Web of Science Science Citation Index Expanded (SCIE)
Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers welcomes submissions of the following article types: Brief Research Report, Case Report, Clinical Trial, Correction, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact email@example.com
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact firstname.lastname@example.org